Compare WSFS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WSFS | EWTX |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | WSFS | EWTX |
|---|---|---|
| Price | $64.64 | $28.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $68.75 | $34.71 |
| AVG Volume (30 Days) | 394.4K | ★ 1.1M |
| Earning Date | 01-26-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 5.09 | N/A |
| Revenue | ★ $1,016,779,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.94 | N/A |
| P/E Ratio | $12.72 | ★ N/A |
| Revenue Growth | ★ 3.23 | N/A |
| 52 Week Low | $42.44 | $10.60 |
| 52 Week High | $64.75 | $30.48 |
| Indicator | WSFS | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.38 | 56.68 |
| Support Level | $57.33 | $27.58 |
| Resistance Level | $60.35 | $29.64 |
| Average True Range (ATR) | 1.63 | 1.57 |
| MACD | 0.81 | 0.01 |
| Stochastic Oscillator | 94.28 | 68.86 |
WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.